Skip to search formSkip to main contentSkip to account menu

MK 0646

Known as: MK-0646, MK0646 
National Institutes of Health

Related topics

Related topics

2 relations
Monoclonal Antibodies

Broader (1)

dalotuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma
Significance Most preclinical drug screening systems fail to predict whether a given drug candidate will succeed in clinical… 
2014
2014
Ezrin expression and cell survival regulation in colorectal cancer.
2014
2014
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients… 
2014
2014
NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer
The insulin-like growth factor receptor is a potential target in small-cell lung cancer. We conducted a phase I study of… 
2013
2013
In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer
The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is… 
Highly Cited
2012
Highly Cited
2012
A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors
Neuroendocrine tumor (NET) cell lines frequently express both insulin‐like growth factor (IGF) ligand and the cognate IGF‐1… 
Highly Cited
2011
Highly Cited
2011
Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma that lacks effective therapeutic strategies. We gain… 
2011
2011
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.
4026 Background: IGF-1R activation results in the phosphorylation of IRS-1 and the PI3-Kinase/Akt, mTOR and S6 kinase pathways in… 
2010
2010
Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.
4039 Background: MK-0646 binds to IGF-1R and blocks its interaction with IGF-I/ II ligands, enhances gemcitabine (G)-induced… 
2009
2009
A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer.
4127 Background: Evidence of cross-talk between EGFR and IGFR signaling pathways provide a logical rationale for combining anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)